Pay attention to the subject matter of reasonable valuation. This week, all A-Shares rose by 2.24% (weighted average of total market value), CSI 300 rose by 2.23%, gem index rose by 2.51%, biomedical sector fell by 2.01% as a whole, and the performance of biomedical sector was weaker than that of the overall market. In terms of molecular section, the largest declines were Pharmaceutical Commerce (- 2.96%), biological products (- 2.86%) and traditional Chinese medicine (- 2.15%). Pharmaceutical and biological P / E ratio (TTM, overall method, excluding negative value) is 23.54x, at a historical low of nearly five years. In terms of sub sectors, sub sectors below 20 times PE include medical devices (15.15x), pharmaceutical commerce (18.99x) and traditional Chinese medicine (19.60x).
It is suggested to pay attention to the relevant targets of boom track with high innovation attribute: A shares: Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) , Jiangsu Hengrui Medicine Co.Ltd(600276) , Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , Wuxi Apptec Co.Ltd(603259) , Apeloa Pharmaceutical Co.Ltd(000739) , Apt Medical Inc(688617) , Bgi Genomics Co.Ltd(300676) , Zhejiang Orient Gene Biotech Co.Ltd(688298) , etc. Hong Kong stocks: Kingsley biotechnology, Corning Jerry pharmaceutical-b, xianruida medical-b, Qiming medical-b, etc.
The national health plan of the 14th five year plan promotes the development of traditional Chinese medicine, pharmaceutical industry and assisted reproductive industry. On May 20, the general office of the State Council issued a notice on printing and distributing the national health plan for the 14th five year plan. The plan emphasizes promoting the inheritance and innovative development of traditional Chinese medicine, promoting the innovative development of pharmaceutical industry, strengthening disease prevention and eugenics.
TAVR services and consumables have been included in Shanghai medical insurance to accelerate the penetration of interventional therapy for cardiovascular diseases. On May 18, the Shanghai Medical Insurance Bureau issued the notice on the trial performance-based payment of some medical consumables, which paid the consumables of heart valve (folding) and cardiac ultrasound catheter on a trial basis. The pilot assessment was officially implemented on June 15 for a period of two years. On January 12, Shanghai included TAVR in the list of payment scope of basic medical insurance, and the charging standard was 5200 yuan. This year marks the 20th anniversary of the world's first TAVR implantation. The inclusion of TAVR in medical insurance is expected to accelerate the penetration of innovative therapies.
Vv116 treatment data was released for the first time, and innovative pharmaceutical enterprises, cdmo, API and other industries welcomed the spring breeze. On May 18, the national infectious diseases Medical Center, Professor Zhang Wenhong's team of Huashan infection and Professor Fan Xiaohong's team of Shanghai Public Health Clinical Center completed an open and prospective cohort study to evaluate the effect of vv116 on the negative time of covid-19 virus nucleic acid in patients with non severe Omicron infection, which was published in the journal emerging microbes & infections. The data showed that the average number of negative days of Omicron infected people using vv116 was 3.52 days; Among the patients who used vv116 within 5 days after the first positive nucleic acid test, the average time of turning negative was 8.56 days, which was less than 11.13 days in the control group.
Risk warning: the risk that the epidemic recovery is less than expected; Medical insurance fee control, centralized purchase and price reduction of drugs and high-value consumables exceeded expectations; The progress of product research and development is less than expected.
